Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda, PeptiDream Expand Collaboration into Neurodegenerative Disease Area
July 28, 2021
- Daiichi Sankyo Espha, Meiji Pharma Launch Cymbalta Generics
July 28, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
- Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
- Lenvima/Keytruda Gets Full US Approval for Endometrial Carcinoma
July 27, 2021
- Meiji Pharma Licenses Stelara Biosimilar to India’s Intas
July 26, 2021
- Rohto Begins Japan PIII for Topical Ganciclovir in CMV Corneal Endotheliitis
July 21, 2021
- Relugolix Combination Drug Approved in EU for Uterine Fibroids
July 21, 2021
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Sanofi to Transfer Plaquenil’s Japan Marketing Rights to Asahi Kasei on Oct. 1
July 20, 2021
- Ono Initiates PII Trial of BTK Inhibitor Velexbru for PCNSL in US
July 20, 2021
- Shionogi Bags Rights to COVID-19 Nasal Vaccines
July 20, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa to Launch Cymbalta Generics on Aug. 30, Nipro on July 21/27
July 19, 2021
- Shionogi’s Peptide Vaccine Fails in PIII for Esophageal Cancer
July 19, 2021
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…